A Amadio1, R Burkes2, T Bailie1, M McLean1, B Coleman1. 1. Department of Pharmacy, Mount Sinai Hospital, Toronto, ON. 2. Department of Oncology, Mount Sinai Hospital, Toronto, ON.
Abstract
BACKGROUND: Delays in chemotherapy because of neutropenia may be associated with poorer outcomes. The purpose of the present study was to examine the effect that granulocyte colony-stimulating factors (g-csfs) have on survival. METHODS: We conducted a chart review of all outpatients diagnosed with metastatic colorectal cancer and treated with folfiri chemotherapy (irinotecan, 5-fluorouracil, leucovorin) with or without bevacizumab at Mount Sinai Hospital between 2007 and 2012. Multivariable Cox proportional hazards models were used to compare survival in neutropenic patients treated with g-csf, in neutropenic patients not so treated, and in patients without neutropenia. RESULTS: The review identified 93 patients, 31 of whom did not experience a neutropenic event. Of the 62 who experienced neutropenia, 18 were managed with g-csf support, and 44, with reductions or delays in dose. Compared with patients experiencing a neutropenic episode not treated with g-csf, those treated with g-csf experienced a nonsignificant increase in time to event [progression or death: hazard ratio (hr): 1.37; 95% confidence limits (cl): 0.72, 2.61], but compared with patients not having a neutropenic episode, the same patients experienced a significant increase in time to event (hr: 2.07; 95% cl: 1.03, 4.15). CONCLUSIONS: In patients who experienced neutropenia, g-csf did not have a statistically significant impact on survival. Time to event was prolonged in g-csf-treated patients compared with patients who did not experience neutropenia.
BACKGROUND: Delays in chemotherapy because of neutropenia may be associated with poorer outcomes. The purpose of the present study was to examine the effect that granulocyte colony-stimulating factors (g-csfs) have on survival. METHODS: We conducted a chart review of all outpatients diagnosed with metastatic colorectal cancer and treated with folfiri chemotherapy (irinotecan, 5-fluorouracil, leucovorin) with or without bevacizumab at Mount Sinai Hospital between 2007 and 2012. Multivariable Cox proportional hazards models were used to compare survival in neutropenicpatients treated with g-csf, in neutropenicpatients not so treated, and in patients without neutropenia. RESULTS: The review identified 93 patients, 31 of whom did not experience a neutropenic event. Of the 62 who experienced neutropenia, 18 were managed with g-csf support, and 44, with reductions or delays in dose. Compared with patients experiencing a neutropenic episode not treated with g-csf, those treated with g-csf experienced a nonsignificant increase in time to event [progression or death: hazard ratio (hr): 1.37; 95% confidence limits (cl): 0.72, 2.61], but compared with patients not having a neutropenic episode, the same patients experienced a significant increase in time to event (hr: 2.07; 95% cl: 1.03, 4.15). CONCLUSIONS: In patients who experienced neutropenia, g-csf did not have a statistically significant impact on survival. Time to event was prolonged in g-csf-treated patients compared with patients who did not experience neutropenia.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Charles L Vogel; Marek Z Wojtukiewicz; Robert R Carroll; Sergei A Tjulandin; Luis Javier Barajas-Figueroa; Brian L Wiens; Theresa A Neumann; Lee S Schwartzberg Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: J Randolph Hecht; Madhavan Pillai; Russell Gollard; William Heim; Forrest Swan; Ravi Patel; Lyndah Dreiling; May Mo; Imtiaz Malik Journal: Clin Colorectal Cancer Date: 2010-04 Impact factor: 4.481
Authors: Matthias Schwenkglenks; Ruth Pettengell; Christian Jackisch; Robert Paridaens; Manuel Constenla; André Bosly; Thomas D Szucs; Robert Leonard Journal: Support Care Cancer Date: 2010-03-20 Impact factor: 3.603
Authors: Seema Gupta; Pankaj K Singh; Madan L B Bhatt; Mohan C Pant; Rajeev Gupta; Mahendra P S Negi Journal: Biosci Trends Date: 2010-10 Impact factor: 2.400
Authors: Brandon L Ellsworth; Allan K Metz; Nicole M Mott; Ruby Kazemi; Michael Stover; Tasha Hughes; Lesly A Dossett Journal: Ann Surg Oncol Date: 2022-02-06 Impact factor: 5.344